|Day Low/High||2.06 / 2.15|
|52 Wk Low/High||2.30 / 5.30|
Gilead Sciences is nearing the completion of two phase III studies of the Jak inhibitor momelotinib in myelofibrosis, a disease affecting bone marrow.
Conference Call Scheduled for 4:30 p.m. EDT Today, November 3
Geron (GERN) announced on Monday that it agreed to a licensing deal with Janssen Pharmaceuticals worth $80 million.
Conference Call Scheduled for 8:00 a.m. EDT Today, September 12
Conference Call Scheduled for 4:30 p.m. EDT Today, August 3
Trade-Ideas LLC identified Geron (GERN) as a strong on high relative volume candidate
Investors in Geron Corp. saw new options become available today, for the July 15th expiration.
Conference Call Scheduled for 4:30 p.m. EDT Today, May 5
Investors in Geron Corp. saw new options become available today, for the December 16th expiration.
TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: AMT, CRHM, CXW, IR, ITG, NWN, PDEX, RDC, RTRX, VCO Downgrades: BK, CEB, CSU, FGBI, GERN, MITT, RLH, SMLP, SMP Initiations: AINC, IZEA Read on to get TheStreet Quant Ratings' detailed report:
Conference Call Scheduled for 4:30 p.m. EST Today, February 25
Investors in Geron Corp. saw new options become available this week, for the April 15th expiration.
Trade-Ideas LLC identified Geron (GERN) as a weak on high relative volume candidate
Investors eyeing a purchase of Geron Corp. shares, but tentative about paying the going market price of $3.24/share, might benefit from considering selling puts among the alternative strategies at their disposal.